Data Pharmacokinetics Meloxicam Mouse

Data concerning the following project/manuscript:

Suitability of prolonged meloxicam treatment in mice seems limited due to unfavorable pharmacokinetics, side effects, and impact on home-cage behaviors

Aylina Glasenapp, Jens P. Bankstahl, Heike Bähre, Jana Hauser, Amisha R. Parmar, Andrey V. Kozlov, Silke Glage, Rupert Palme, Marion Bankstahl

Meloxicam is commonly used for analgesia, but no preparation approved for mice. Here, we determined plasma concentrations, safety, anti-nociceptive activity and impact on home-cage behaviors for subcutaneous injection (5 mg/kg) and oral self-intake (sweetened drinking water, 20 mg/kg/24h, 5 days) for C57BL/6J mice (n=21/sex). After injection, plasma concentrations measured by LC-MS/MS were higher in females (2h) and remained within an estimated therapeutic range (390–911ng/mL) for up to 6h. T1/2 was 2.32 h. Despite acceptance, plasma levels fluctuated strongly during oral self-intake. No anti-nociceptive effect was found (tail-immersion test). Side effects comprised reduced grip strength and increased vocalization (Irwin test), increased clinical score values (females, oral treatment) with two individuals reaching humane endpoint, increase in body temperature, body weight drop, decreased wheel-running activity, increased burrowing latency (males), and prolonged grooming activity (females). Grimace scale, nesting activity and plasma corticosterone remained unaffected. Red blood profile parameters and ALT were decreased and Ca2+ and Cl- concentrations elevated. Histopathological analysis revealed inflammatory cells and hyperplasia in stomach and jejunum. In view of the unfavorable pharmacokinetics, meloxicam treatment via the drinking water is unsuitable in mice. The limited tolerability and the lack of anti-nociceptive effect make prolonged treatment with the doses studied appear inappropriate.

Data were aquired at MHH by Aylina Glasenapp et al.